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Purpose: Interleukin-1β (IL-1β) and S100B calcium binding protein B (S100B) have been 
implicated in the pathogenesis of Alzheimer’s disease. Both are present in and around senile 
plaques and have been shown to increase levels of amyloid precursor protein (APP) mRNA 
in vitro. However, it is not known how either of these substances affects APP in vivo.
Methods: We have studied the effects of IL-1β and S100B on the expression and processing 
of APP using a retinal-vitreal model. We have also investigated the effect of amyloid beta 
peptide (Aβ) on APP in the same system and the regulation of S100B production by Aβ and 
IL-1β from retinal glial cells.
Results: Retinal ganglion cells constitutively express APP. However, after intravitreal injection 
of IL-1β or Aβ there was a marked reduction in APP levels as detected by Western blotting 
and IL-1β produced a decrease in APP immunoreactivity (IR). Nissl staining showed that the 
integrity of the injected retinas was unchanged after injection. Two days after S100B injection, 
there was a small reduction in APP-IR but this was accompanied by the appearance of some 
intensely stained large ganglion cells and there was some up-regulation in APP holoprotein 
levels on Western blot. Seven days post-S100Β injection, these large, highly stained cells had 
increased in number throughout the retina. Injection of Aβ and IL-1β also caused an increase 
in S100B production within the retinal Müller glial cells.
Conclusion: These results support the hypothesis that S100B (a glial-derived neurotrophic 
factor) and IL-1β (a pro-inﬂ ammatory cytokine) can modulate the expression and processing 
of APP in vivo and so may contribute to the progression of Alzheimer’s disease.
Keywords: Alzheimer’s disease, interleukin 1β, S100B, amyloid precursor protein, amyloid-β, 
retina
Introduction
The neuropathological hallmarks of Alzheimer’s disease (AD) are senile plaques and 
neuroﬁ brillary tangles. The plaques are comprised of a variety of peptides, the most 
abundant of which is amyloid beta peptide (Aβ) and it is thought the abnormal cleavage 
of amyloid precursor protein (APP) by β- and then γ-secretase yields this pro-aggrega-
tory Aβ peptide (Hardy 1997). These plaques are intimately associated with activated 
microglial cells interdigitating the plaques and astrocytes surrounding the plaques. It 
has been shown that these cells over-express pro-inﬂ ammatory factors such as S100B 
and interleukin-1 beta (IL-1β) (Grifﬁ n et al 1995; Mrak et al 1996).
S100Β is a small 10 kDa protein belonging to the EF-hand family of calcium binding 
proteins and is released from astrocytes and Schwann cells (Donato 2001). At lower 
doses (high picomolar to low nanomolar), S100B displays neurotrophic properties by 
increasing neuronal survival and promoting neurite outgrowth (Kligman et al 1985; 
Bhattacharyya et al 1992). However, at higher doses, S100B stimulates astrocytes and 
microglia to produce pro-inﬂ ammatory cytokines including IL-1β (Kim et al 2004). 
Studies from Sheng and colleagues (1996) suggest that early plaques are accompanied 
by large numbers of astrocytes expressing S100B whilst at later stages there are far 
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fewer S100B-positive astrocytes, implying a role for this 
factor in early plaque development. This is further supported 
by evidence showing that in the APP-over expressing mouse, 
APPV717F mice, increased levels of S100B precede the 
deposition of Aβ (Sheng et al 2000). Whether S100B causes a 
direct increase in Aβ production or whether it is a secondary 
increase remains to be determined.
Interleukin-1β (17 kDa) is a pro-inﬂ ammatory cytokine 
having a multitude of different actions. Microglial cells 
within senile plaques have been shown to increase their pro-
duction of IL-1β and this expression increases with plaque 
pathology; ﬁ nally disappearing at the end stage “burnt-out” 
plaques (Mrak and Grifﬁ n 2001). Again, it would appear that 
IL-1β may be involved in production of Aβ, but whether it is 
cause or effect is still unclear. IL-1β increases the expression 
of APP mRNA in cultured cells by acting on its promoter 
(Goldgaber et al 1989; Buxbaum et al 1992) and may regulate 
the increase in APP expression after traumatic brain injury 
(Ciallella et al 2002). Accumulation of APP may lead to 
increased production of Aβ – the central core of amyloid 
plaques. Increased Aβ could then cause the stimulation of 
glial cells resulting in further expression of S100B. S100B 
may stimulate the release of IL-1β from microglia and so a 
“cytokine cycle” is initiated, perpetuating the damage (Grifﬁ n 
et al 1998). However, the direct actions of S100B and IL-1β 
on APP production and processing in vivo are unclear. To 
address this issue, we have used a rat retinal-vitreal model 
to study the effects of these cytokines on APP expression 
in vivo. This is a potentially useful model because retinal 
ganglion cells (RGC) constitutively express APP (Morin 
et al 1993) and the closed nature of the system means that 
the injected substances remain in situ rather than being 
rapidly cleared, giving them the opportunity to act locally. 
Furthermore, the retina contains most of the nerve cells that 
express AD-associated molecules, all the major neurotrans-
mitter-producing neurons and most of the glial populations 
found in the brain (Guo et al 1991, 1992a, 1992b; Yang et al 
1992; Chen et al 1996; Bresciani et al 2002; Walsh et al 2005; 
Watts et al 2007), thus enabling us to study the interplay of 
these cytokines within a central nervous system setting.
Materials and methods
All experimental procedures were carried out in accordance 
with the Animals (Scientiﬁ c Procedures) Act 1986. Female 
Sprague-Dawley rats (6–8 weeks old) were anaesthetised 
with sodium pentobarbital (0.6 ml/100 g) and underwent uni-
lateral intravitreal injection with either S100B (Sigma, UK; 2 
and 5 nmol in 3 μl vehicle; n = 6 per dose); rat recombinant 
IL-1β (Serotec, UK; 150 and 1500U in 3 μl; n = 9 per dose), 
the higher dose based on a study by Bamforth and colleagues 
(1997); aggregated Aβ
1–42
 (Bachem, UK; 2 nmol in 3 μl; 
n = 12) or phosphate-buffered saline (PBS) (n = 6). Aβ
1–42
 
was aggregated by incubation at 37 °C for 4 days in PBS 
(Jen et al 1998; Walsh et al 2002). Before injection, some of 
the vitreous humour was removed to avoid increased intra-
ocular pressure. At 2 and 7 days after injection, animals were 
either killed by cervical dislocation and the retinas removed 
for Western blotting or they were transcardially perfused 
with saline followed by 4% paraformaldehyde (PFA) and 
processed for immunohistochemistry (IHC; n = 3 for each 
treatment). Aβ
1–42
-injected animals were killed at 2 days.
For Western blotting (n = 3 for each treatment), retinas 
were rapidly removed and snap frozen in liquid nitrogen. 
Retinas were homogenised in RIPA buffer (150 mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, in 50 mM 
Tris, pH 8.0). A cocktail of protease inhibitors (CompleteMiniTM, 
Roche) was always added fresh to the lysis buffer to avoid 
nonspecific digestion of proteins. Retinal homogenates 
(30 μg/lane) underwent electrophoresis on 4%–12% BisTris 
gels (NuPAGE System, Invitrogen) and were then blotted 
onto nitrocellulose membranes. Blots were blocked in 5% 
dried skimmed milk in PBS/0.1% Tween 20 (blocking 
buffer) for at least 1 hour prior to incubation with either 
CT695 anti-APP antibody (Zymed, Laboratories Inc, USA; 
1:200 dilution) or anti-S100B antibody (Sigma Chemical 
Company Ltd, Poole, UK; 1:1000 dilution) overnight at 
4 °C. Blots were washed and then incubated for 1 hour with 
peroxidase-conjugated anti-rabbit antibody (Sigma Chemi-
cal Company Ltd, Poole, UK; 1:3000) in blocking buffer. 
Bound immunoglobulins were detected with the ECL system. 
Some blots were stripped of the antibodies using ReBlotTM 
(Chemicon, Harrow, UK) and then re-probed with alpha-
actin antibody (Roche, Lewes, UK; 1:2000) to visualize the 
protein load per lane.
For IHC, eyes were removed, post-ﬁ xed in 4% PFA (4 h) 
and sunk in sucrose overnight. The eyes were then embedded 
in OCT and frozen in isopentane pre-cooled in liquid nitrogen. 
Sections were cut at a 20 μm thickness and mounted onto 
SuperFrost® Plus slides (VWR International). Sections were 
washed in 0.1 mM PBS/0.3% Triton X-100 (Sigma, UK); 
endogenous peroxidases were blocked with H
2
O
2
 in methanol; 
and microwaved in EDTA, at 40% power for 4 min. Sections 
were then blocked in normal serum before addition of the 
primary antibody overnight, either CT695 anti-APP (1:1000 
dilution) or anti-S100B (1:1000 dilution). Sections were 
washed and incubated with biotinylated secondary antibody 
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(Vector, Peterborough, UK) for 45 minutes followed by 
further washing and incubation in Vectastain Elite ABC kit for 
45 minutes (Vector, Peterborough, UK). Staining was visual-
ized using the diaminobenzidine (DAB) peroxidise substrate 
kit (Vector, Peterborough, UK). APP-staining also included 
nickel enhancement. For staining with anti-S100B antibody, 
the microwave step was omitted. Sections were dehydrated in 
an increasing alcohol gradient, cleared in xylene and mounted 
with DPX resin (BDH Chemicals Ltd, Poole, UK).
For Nissl staining to reveal the cytoarchitecture, sections 
were stained with cresyl fast violet (Raymond A Lamb, East-
bourne, UK) for 5 minutes, washed in PBS and dehydrated in 
an increasing alcohols gradient and mounted with DPX.
Results
APP immunoreactivity is altered
by IL-1β and S100B
We have set out to address how APP processing is affected 
by IL-1β and S100B in projection neurons of the rat retina. In 
control animals, APP, as detected with a C-terminal directed 
antibody (CT695, Zymed), is constitutively expressed in 
the RGC throughout the ganglion cell layer with some 
staining seen in the axons of these cells. This pattern of 
staining was unchanged by intravitreal injection of PBS at 
2 days (Figure 1a and b) or by injection of the lower dose of 
IL-1β (150 U/3 μl, not shown) and S100B (2 nmoles/3 μl, 
not shown). However, 2 days after intravitreal injection 
with higher dose IL-1β (1500 U/3 μl) there was a marked 
decrease in immunoreactivity (IR) throughout the ganglion 
cell layer with loss of staining in the RGC (Figure 1c). In the 
retinas injected with a higher dose of S100B (5 nmol/3 μl), 
there appeared to be a small decrease in the overall stain-
ing within the ganglion cell layer but this was accompanied 
by the appearance of a small number of ganglion cells that 
showed very strong APP-IR (Figure 1g and h). Seven days 
after injection with S100B, the number of these intensely 
stained RGCs appeared to increase (Figure 1i and j). Simi-
lar large, heavily stained cells also became apparent 7 days 
after injection with high dose IL-1β (Figure 1e and f). As the 
injected Aβ
1–42
 cross-reacted with the CT695 antibody, we 
were unable to ascertain the changes in APP-IR after injec-
tion of the peptide. Since we only noted changes with the 
higher doses of cytokines tested, we continued to use these 
doses for further studies.
To ensure that our injection procedures were not deplet-
ing cells within the granule cell layer (GCL), we looked 
at Nissl staining of sections injected with PBS, IL-1β, and 
S100B. The staining revealed that there was no change in the 
cytoarchitecture of the retinas after injection with S100B and 
we could not detect any pyknotic bodies. After injection with 
IL-1β, there was the appearance of a cellular inﬁ ltrate in some 
of the injected animals but the cells within the GCL appeared 
healthy with no sign of pyknotic bodies (Figure 2).
Differential effects of IL-1β, S100Β,
and Aβ1–42 on APP processing
We have used IHC to look at the cellular proﬁ le of APP 
changes but this does not allow us to study its processing. 
We therefore used Western blotting to investigate how each 
cytokine affected the processing of APP. Using the same anti-
body in the Western blots, APP appears as a cluster of bands 
at 98 kDa and a single band at 54 kDa, as shown previously 
(Croucher et al 2003). Two days after injection with IL-1β 
or Aβ
1–42
 there was a marked decrease in the 54 kDa band in 
the injected as compared with noninjected eyes (Figure 3a 
and Figure 3c, respectively) and a decrease in the 98 kDa 
band after Aβ
1 42
 (Figure 3c). After injection with Aβ
1 42
 there 
was also the appearance of lower molecular weight bands 
at around 13 kDa and a band at approx 82 kDa (Figure 3c). 
Interestingly, we were not able to detect the same band pat-
tern in retinas from eyes injected with S100B, even though 
there was an up-regulation of the 98 kDa band (Figure 3b). 
Figure 2b also shows faint band fragments at approximately 
30 kDa and at 37 kDa in injected and noninjected eyes. 
Seven days after injection of IL-1β, the 98 and 54 kDa bands 
had returned to the same levels as the noninjected eyes (not 
shown). Again, seven days after S100B injection, there was 
no difference in the levels and band pattern of APP between 
injected and noninjected eyes (not shown).
S100B is up-regulated by Aβ1–42
and IL-1β in vivo
As S100B appeared to be up-regulating APP expression in a 
sub-population of the RGCs and has been implicated in AD, 
we wanted to see how this cytokine is itself regulated by IL-1β 
and Aβ
1–42
. In naïve, untreated retinas, S100B is constitutively 
expressed in the Müller glial cell end feet in the ganglion cell 
layer (Figure 4a). Injection of PBS caused a slight increase in 
S100B staining (Figure 4b). After injection with aggregated 
Aβ
1–42
 (2 nmol/3 μl, 2 days post-injection) there was a marked 
up-regulation of S100B in the Müller cell end feet and also 
the Müller cell bodies within the inner nuclear layer as well 
as the appearance of staining throughout the Müller cell radial 
processes (Figure 4c). Interestingly, we also noted an increase 
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in S100B staining in the contralateral retina (not shown). 
Western blotting with an anti-S100B antibody showed the 
appearance of a strong band around 15 kDa, corresponding 
to S100B after injection with Aβ
1–42
 (Figure 4e). The 7 kDa 
band seen in lanes loaded with recombinant S100Β probably 
represents the monomer, whereas the 15 kDa band in the left 
(injected) eye probably represents the biologically active 
homodimer of S100B. There was no increase in S100B stain-
ing 2 days after injection of IL-1β (data not shown). However, 
there was a marked increase in S100B in the Müller glial 
cells 7 days after injection of IL-1β (Figure 4d) and, again, 
we noted a contralateral effect with increased S100B in the 
noninjected eye (data not shown).
Discussion
This study has highlighted the differential effects of two 
amyloid plaque-associated factors and Aβ
1–42
 on the expres-
sion and processing of APP. Injection of IL-1β resulted in 
the reduction of APP-IR in RGCs and, along with injection 
of Aβ
1–42
, a reduction on Western blot. However, injection of 
Figure 1 Photomicrographs showing APP immunoreactivity in rat retinas 2 days post-PBS injection at low (a) and high (b) magnifi cation. Note staining is seen in the GCL 
with some axonal staining. Low magnifi cation photomicrograph showing that APP immunoreactivity is decreased in retinas injected with IL-1β after 2 days (c) compared with 
low magnifi cation micrograph the retina from the corresponding noninjected eye (d). Low (e) and high (f) magnifi cations of retinas 7 days post-IL-1β injection show recovery 
of APP staining of RGCs. Low and high magnifi cations of retinas 2 days post-S100Β injection show sporadic RGCs strongly stained for APP. Low (i) and high (j) magnifi cations 
of retina 7 days post-S100B injection indicating an increase in RGC immunoreactivity.
Note: Scale bar = 50 μm.
Abbreviations: APP, amyloid precursor protein; GCL, granule cell layer; IL, interleukin; RGC, retinal ganglion cells; PBS, phosphate-buffer solution.
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Figure 2 Nissl staining of (a) normal retina, (b) retina 2 days after injection with S100B and (c) retina 2 days after injection with IL-1β. Note that the tissue architecture is 
not affected by the injection and that the GCL layer appears intact without loss of the large ganglion cells.
Abbreviations: GCL, granule cell layer; IL, interleukin.
B B
Figure 3 Western blotting of APP in retinas injected with (a) IL-1β, (b) S100B, (c) Aβ1–42 peptide, and (d) PBS 2 days after injection. Each panel shows 2 animals per treatment. 
Both IL-1β and Aβ1–42 show a marked reduction in APP levels in the injected left eye (L) compared with the noninjected right eye (R), particularly in the 54 kDa band. There 
was no down-regulation after injection with S100B or PBS. Note also the appearance of bands around 13 kDa and 82 Kda after injection with Aβ1–42.
Abbreviations: APP, amyloid precursor protein; IL, interleukin; PBS, phosphate-buffer solution.
S100B appears to increase APP levels in a population of the 
RGC (Figure 1g–j) and an up-regulation of the 98 kDa APP 
band (Figure 3b) as well as the appearance of faint protein 
bands at approximately 30 kDa and 37 kDa.
The reduction in APP induced by IL-1β and Aβ
1–42
 
appears to be widespread throughout the ganglion cell layer. 
The reason for this APP down-regulation is unclear but it may 
be that it is a stress response of the peptide itself. In vivo, it 
has previously been demonstrated that some cytokines can 
down-regulate APP as well as the anti-apoptotic protein, 
Bcl-2, levels in the rat retina (Chen et al 1999). This appears 
to contradict studies that have shown that IL-1β can increase 
mRNA for APP (Goldgaber et al 1989; Buxbaum et al 1992), 
but may reﬂ ect the differences between the in vitro and 
in vivo systems. Whether we are observing a decrease in the 
production of APP, an increase in metabolism or both remains 
to be fully established, but we have observed, particularly 
after Aβ
1–42
 injection, lower molecular weight bands that may 
represent breakdown products. In vitro evidence has shown 
that IL-1β alone and in combination with other cytokines can 
induce the production of soluble APPs (sAPPs) or α-cleaved 
APPs (αAPPs) from a neuronal cell line stably transfected 
with APP. In combination with interferon-γ, there was also 
an increase in secreted Aβ peptides in the same system 
(Sastre et al 2003). These changes occurred in the absence of 
a change in the cell-associated APP levels and so are likely 
to be a direct consequence of APP processing.
The APP band pattern produced in the retinas exposed 
to Aβ
1–42
 is of particular interest since it appears similar to 
that of retinas exposed to the broad spectrum metabotropic 
glutamate (mGlu) receptor agonist, (1S,3R)-1-aminocyclo-
pentane-1,3-dicarboxylic acid ((1S,3R)-ACPD) (Croucher 
et al 2003). The APP fragment that appears between the 
98 kDa holoprotein and the 54 kDa fragment may be an 
82 kDa non-amyloidogenic soluble fragment (sAPP) formed 
from metabolism of APP by α-secretase leading to proteolyic 
cleavage within the Aβ region (Figure 3c). Croucher and 
colleagues (2003) also demonstrated that fragments of APP 
metabolism can be secreted into the vitreous ﬂ uid of rat eyes 
after stimulation with this mGlu receptor agonist and, in view 
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of the similarity in the retinal APP Western blot band pattern, 
it is likely that the same is happening here.
IL-1β has been shown to cause changes in APP levels 
in other cell systems in vitro. In U-373 MG astrocytoma 
cells, IL-1β caused an increase in αAPPs (Gitter et al 2000), 
whilst in the PC12 cell line, IL-1β enhanced the secretion 
of N-terminal fragments of APP, again reﬂ ecting increased 
processing of APP (Dash and Moore 1995).
Our Western blots showed a greater reduction in the 54 kDa 
band compared with the 98 kDa, especially after IL-1β injection 
(Figure 3a). It would appear that this band is more sensitive to 
the degradation process than the 98 kDa band. Interestingly, 
this 54 kDa band has also been identiﬁ ed in the neuromuscular 
junction, which, like the retina, is rich in cholinergic innerva-
tions (Dash and Moore 1995) and may imply that cholinergic 
innervation exerts some control over APP levels. It remains 
to be seen if the IL-1β- or Aβ
1–42
-induced metabolism of APP 
yields amyloidogenic Aβ
1–42
 in this in vivo model.
S100B induced a small decrease in APP-IR in the RGC 
(Figure 1g and h), though not as marked as with IL-1β 
(Figure 1c and d), suggesting that S100B may not be initiat-
ing such a severe response as the other mediator. However, 
Figure 4 S100B immunostaining in (a) noninjected rat retina shows that there is normal expression of the protein in the Müller cell endfeet. (b) S100B is only slightly increased 
after injection of PBS. (c) 2 days after injection of Aβ1–42 there is a marked up-regulation of S100B in the Müller cell endfeet, cell bodies (arrowhead) and processes (arrows) 
throughout the retina. (d) There was also a marked increase in S100B immunoreactivity 7 days after injection of IL-1β. (e) The increase in S100B after Aβ1–42 injection was 
confi rmed by Western blotting. Recombinant bovine S100B is shown in lanes 1–3 and forms two bands at 7 and 19 kDa. Injection of Aβ1–42 caused strong expression of a single 
15 kDa band in the injected left eye (L) compared with a comparatively weak expression in the noninjected, right eye (R).
Abbreviations: PBS, phosphate-buffer solution.
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we also noted the appearance of some large, intensely APP-IR 
cells within the retinal ganglion cell layer (Figure 1 g–j). This 
was accompanied by marked up-regulation the 98 kDa APP 
holoprotein in the injected and noninjected eyes of rats treated 
with S100B as determined by Western blot (Figure 3b); that 
is, S100β induced a contralateral effect on APP biosynthesis. 
It may be that the increase in the APP levels in these large 
ganglion cells is masking the small loss of APP seen in IHC. 
The appearance of faint bands at approximately 30 kDa and 
37 kDa in Figure 3b might reﬂ ect a different APP metabolism 
to that produced by injection of Aβ
1–42
.
To our knowledge, this is the ﬁ rst study that directly links 
S100B to increases in APP in vivo. S100B has been shown 
to cause an increase in APP protein and message in neurones 
from primary culture of rat foetal cortex (Li et al 1998). At 
low doses, S100B promotes neurite outgrowth (Kligman and 
Marshak 1985) and enhances neuronal survival after injury 
and during development (Winningham-Major et al 1989). 
Given its role in axonal transport, the appearance of increased 
APP may indicate that that these cells are undergoing some 
aberrant sprouting/neuritic outgrowth. The observation of 
increased APP in a subset of projection neurons may have 
important implications in AD. Astrocytes over-expressing 
S100B have been found to correlate with the proliferation of 
dystrophic neurites over-expressing APP in the cortex and 
within plaques in AD patients (Mrak et al 1996) and here we 
provide direct evidence that S100B can induce increases in 
neuronal APP in an animal model. Interestingly, we noted 
the appearance of a small number of densely stained RGCs 
7 days after the injection of IL-1β. Our results show that an 
intravitreal injection of IL-1β causes a prolonged increase 
in S100B staining in Müller glia (Figure 4d) and exposure 
to Aβ
1–42
 up-regulates retinal S100β two days after injec-
tion (Figure 4c). This may suggest that IL-1β-stimulated 
release of S100B is causing this delayed increase in cells 
over-expressing APP – an observation that warrants further 
investigation. The increase in S100Β staining seen after IL-
1β and Aβ
1–42
 seen here is similar to the increase in GFAP 
in Müller glia seen after Aβ
1–42
 treatment (Bamford et al 
1997; Walsh et al 2002), optic nerve crush, and intravitreal 
lipopolysaccharide injection (data not shown) and highlights 
that this response is not speciﬁ c to any particular treatment 
and is a general marker of astrocytic activation. However, this 
raises the possibility that activation of glial cells, by whatever 
means, may exacerbate the disease progression.
Using a retinal-vitreal system, we have shown that intra-
vitreal injection of either IL-1β or Aβ
1–42
 induce a reduction in 
APP levels probably due to altered metabolism while S100B 
increased APP in a subset of neurons in a time-dependent 
fashion. We have also shown that both Aβ
1–42
 and IL-1β 
up-regulate S100B itself. These changes may have impor-
tant implications in the pathogenesis of AD. Both IL-1β and 
S100B have been shown to be associated with reactive astro-
cytes and dystrophic neurites over-expressing APP and here 
we provide in vivo evidence of a direct link between these 
mediators and APP production and metabolism. It has been 
hypothesised that in AD, a “cytokine cycle” may underlie the 
progression of the disease (Grifﬁ n et al 1998). In this cycle, 
within the environs of senile plaques, Aβ and soluble APP 
cause the release of IL-1β from activated microglia. This in 
turn stimulates the release of S100B from astrocytes and has 
direct effects on APP levels in neurons. Our in vivo evidence 
suggests that S100B is secreted by glial Müller cells in the 
retina; that S100B is able to increase APP expression; and that 
both IL-1β and Aβ
1–42
 increase the processing of APP. Our reti-
nal-vitreal system functions as an ideal in vivo system to study 
the interplay between IL-1β, S100B, Aβ and APP. Future work 
will determine the identities of the APP protein fragments seen 
in the Western blots published in this paper. It may be that the 
IL-1β-S100B cytokine cycle described above, in up-regulating 
APP levels, leads to increased production of the ﬁ brillogenic 
Aβ
1–42
 and the formation of amyloid plaques.
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